Benzinga | Aug 9, 2021 04:10PM EDT

Castle Biosciences Q2 EPS $(0.35) Beats $(0.37) Estimate, Sales $22.80M Beat $18.93M Estimate

Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.37) by 5.41 percent. This is a 337.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $22.80 million which beat the analyst consensus estimate of $18.93 million by 20.44 percent. This is a 79.32 percent increase over sales of $12.71 million the same period last year.